Emergent BioSolutions Inc. (NYSE:EBS) Shares Sold by AQR Capital Management LLC

AQR Capital Management LLC lessened its holdings in shares of Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 56.2% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 460,311 shares of the biopharmaceutical company's stock after selling 591,387 shares during the quarter. AQR Capital Management LLC owned 0.88% of Emergent BioSolutions worth $3,139,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Susquehanna Fundamental Investments LLC acquired a new stake in Emergent BioSolutions during the 1st quarter worth approximately $300,000. BNP Paribas Financial Markets grew its position in Emergent BioSolutions by 155.3% in the first quarter. BNP Paribas Financial Markets now owns 163,589 shares of the biopharmaceutical company's stock valued at $414,000 after acquiring an additional 99,520 shares in the last quarter. Federated Hermes Inc. grew its position in Emergent BioSolutions by 1,314.0% in the second quarter. Federated Hermes Inc. now owns 273,287 shares of the biopharmaceutical company's stock valued at $1,864,000 after acquiring an additional 253,960 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Emergent BioSolutions in the first quarter valued at approximately $57,000. Finally, Vanguard Group Inc. grew its position in Emergent BioSolutions by 14.7% in the first quarter. Vanguard Group Inc. now owns 3,411,549 shares of the biopharmaceutical company's stock valued at $8,631,000 after acquiring an additional 436,911 shares in the last quarter. Institutional investors and hedge funds own 78.40% of the company's stock.

Emergent BioSolutions Stock Up 0.3 %

Shares of EBS stock traded up $0.03 during mid-day trading on Tuesday, reaching $9.23. 1,620,406 shares of the company were exchanged, compared to its average volume of 3,646,981. The company has a debt-to-equity ratio of 1.16, a quick ratio of 0.54 and a current ratio of 1.06. The business's 50 day simple moving average is $8.35 and its 200 day simple moving average is $6.67. The company has a market capitalization of $483.67 million, a P/E ratio of -0.84 and a beta of 1.59. Emergent BioSolutions Inc. has a fifty-two week low of $1.42 and a fifty-two week high of $15.10.

Emergent BioSolutions (NYSE:EBS - Get Free Report) last issued its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($2.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.97) by ($1.35). The company had revenue of $254.70 million during the quarter, compared to the consensus estimate of $199.47 million. Emergent BioSolutions had a negative return on equity of 34.38% and a negative net margin of 53.26%. During the same quarter last year, the firm posted ($1.06) EPS. Research analysts predict that Emergent BioSolutions Inc. will post -1.98 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have issued reports on EBS. Benchmark reaffirmed a "buy" rating and issued a $8.00 price objective on shares of Emergent BioSolutions in a research report on Friday, August 16th. Rodman & Renshaw reaffirmed a "buy" rating and issued a $16.00 price objective on shares of Emergent BioSolutions in a research report on Friday, September 13th.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.